Contrast Enhanced SWI for Carotid Plaque Imaging

Contrast Enhanced Susceptibility Weighted Imaging (SWI) for Characterization of Carotid Plaque

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02749916

Enrollment

Registered

2016-04-25

Start date

2016-08-31

Completion date

2019-12-31

Last updated

2019-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Plaque Imaging

Keywords

SWI, MP-RAGE, DANTE T1-SPACE

Brief summary

This study aims to compare image-based characteristics of carotid walls between symptomatic side and the opposite side. The design of this study is phase IV, prospective observational study.

Detailed description

Atherosclerosis of craniocervical arteries are one of most important causes of stroke. Carotid artery is the most frequent site of atherosclerosis. Recent research in carotid artery covers not only morphology of lumen but also direct visualization of carotid plaque or vessel wall. Vulnerable carotid plaques share pathologic features of intra-plaque inflammation and hemorrhage. There have been reports about post-contrast SWI in the field of vascular imaging. We hypothesized SWI is so sensitive to gadolinium based contrast agent and hemorrhage that contrast-enhanced SWI can visualize vulnerable carotid plaque. The purpose of this study is to investigate gadolinium-enhanced SWI in detection of vulnerable carotid plaque and compare it with MP-RAGE and DANTE T1-SPACE. This can be used to guide proper treatment for stroke.

Interventions

OTHERMethods of carotid wall imaging

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with acute or recent (within 3months) stroke or TIA * 50-99% stenosis of internal carotid artery by NASCET criteria * Written informed consent, prior to registration

Exclusion criteria

* Hemorrhagic stroke * Previous history of carotid endarterectomy (CEA), angioplasty, or stenting * Contraindication for MR imaging * Hypersensitivity to gadolinium based contrast media * Pregnant or lactating women * Patients under age of 19-year-old * Renal condition : eGFR \< 60 * Patients unable and/or unwilling to comply with treatment or study instructions.

Design outcomes

Primary

Measure	Time frame
Detection rate of findings of vulnerable carotid plaque	within 3 days after enrollment

Secondary

Measure	Time frame	Description
Accuracy in delinating geometry of carotid inner lumen and outer wall	within 3 days after enrollment	Diameter of inner lumen and outer wall; Area of inner lumen and outer wall

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026